The Role of Serological Testing and HLA Genotyping in the Diagnosis of Celiac Disease in Slovak Cohort. Can Duodenal Biopsies be Omitted?

Jarmila Kabátová^{1, 2,} and Rastislav Husťak^{3, 2}

¹Gastroenterology Center, Piešťany, Slovak Republic

²Faculty of Health Studies and Social Work, Trnava University, Trnava, Slovak Republic

³1st Faculty of Medicine, Charles University, Prague, Czech Republic

Cite this paper:
Jarmila Kabátová and Rastislav Husťak. The Role of Serological Testing and HLA Genotyping in the Diagnosis of Celiac Disease in Slovak Cohort. Can Duodenal Biopsies be Omitted?. International Journal of Celiac Disease. 2017; 5(3):104-107. doi: 10.12691/ijcd-5-3-9

Abstract

Presented analysis focuses on usefulness of consecutive celiac disease antibodies testing anti-TG2 and EMA, and HLA-DQ2/DQ8 genotyping in symptomatic children and adolescents with suspected celiac disease refered to the latest ESPGHAN guidelines (2012), that permit confirmation of celiac disease without previous duodenal biopsy. A total of 258 children and adolescents (86 male and 172 girls), aged 2 to 18 years, were retrospectively examined performance of celiac disease testing according national guidelines from 2009 included duodenal sampling and the ESPGHAN nonbiopsy criteria in a pediatric population. In applying nonbiopsy criteria to our cohort, 33,3 % (86) of symptomatic children and adolescents with such high anti-TG2 titers and positive EMA could have been initially diagnosed without an intestinal biopsy. All of them presented with advanced intestinal atrophy Marsh 2-3. Part of the rational of the study was to determine sensitivity and specificity, positive and negative predictive values of the final laboratory tests and diagnostic accuracy of the combined tests for antibodies.

Keywords:
celiac disease (CD) ESPGHAN anti-TG2 EMA HLA-DQ2/DQ8

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Figures

References:

[1]	Husby S1, Koletzko S, Korponay-Szabó IR, Mearin ML, Phillips A, Shamir R, Troncone R, Giersiepen K, Branski D, Catassi C, Lelgeman M, Mäki M, Ribes-Koninckx C, Ventura A, Zimmer KP; ESPGHAN Working Group on Coeliac Disease Diagnosis; ESPGHAN Gastroenterology Committee; European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr 2012; 54(1): 136-160.
[2]	Nevoral J, Kotalova R, Hradsky O, Valtrova V, Zarubova K, Lastovicka J, Neubertova E, Trnkova M, Bronsky J. Symptom positivity is essential for omitting biopsy in children with suspected celiac disease according to the new ESPGHAN guidelines, Eur J Pediatr 2013; 173: 497-502.
[3]	Smarrazzo A, Misak Z, Costa S, Mičetić-Turk D, Abu-Zekry M, Kansu A, Abkari A, Bouziane-Nedjadi K, Ben Hariz M, Roma E, Velmishi V, Legarda Tamara M, Attard T, Djurisic V, Greco L, Magazzù G. Diagnosis of celiac disease and applicability of ESPGHAN guidelines in Mediterranean contries: ad real life prospektivite study. BMC Gastroenterology 2017; 17(1): 17.
[4]	Gidrewicz D, Potter K, Trevenen CL, Lyon M, Butzner JD. Evaluation of the ESPGHAN Celiac Guidelines in a North American Pediatric Population. The American Journal of gastroeneterology 2015.
[5]	ISO 15189:2012 (en), Medical laboratiories – Requirements for quality and competence. Availabe from: http://www.osp.org/standart/56115.html.
[6]	Pekárková B, Pekárek B, Kabátová J. Štandardný diagnostický a terapeutický postup. 46. Metodický list racionálnej farmakoterapie. Racionálna diagnostika a liečba celiakie 2009; ročník 13, číslo 1-2, 1-7.